Brainvectis will give presentations at the Congress of the European Society of Gene and Cell Therapy (ESGCT) taking place October 17-20, 2017, in Berlin, Germany.

By October 11, 2017Non class

Nathalie Cartier will give an oral presentation during the Opening session Tuesday 17 october, entitled:

“Clinical gene therapy for neurodegenerative diseases: Past, present, and future”

 

Nathalie Cartier will give another talk on Wednesday 18 october during the session 1b: Ocular and central nervous system gene and cell therapy, entitled :

“AAV-mediated CYP46A1 gene therapy for Huntington’s disease”

 

Sandro Alves will give a short presentation on Wednesday 18 october during session 2a: Ocular and central nervous system gene and cell therapy, entitled :

“AAV-CYP46A1 is beneficial in Alzheimer’s disease: From mice to non-human primates”

These results will be also presented in poster P221.